Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb
Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb
LAVAL, QC / ACCESSWIRE / December 12, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following statement in response to a request from the Canadian Investment Regulatory Organization (CIRO):
拉瓦爾,QC / ACCESSWIRE / 2024年12月12日 / Bausch Health Companies Inc. (紐交所:BHC)(TSX:BHC)("公司"或"Bausch Health"),一家全球多元化的藥品公司,通過不懈努力,改善健康結果,發佈了以下聲明,以回應加拿大投資監管組織(CIRO)的請求:
"As previously disclosed, the Company believes that completing the full separation of its subsidiary, Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), makes strategic sense. The Bausch Health Board of Directors authorized management and management of its subsidiary, Bausch + Lomb, to explore a potential sale, which is one of several options being considered to complete the separation. That process is ongoing. No decision has been reached to proceed with any particular transaction, and there can be no assurance that it will result in a transaction.
「如之前所披露,公司認爲完成其子公司Bausch + Lomb Corporation(紐交所/多倫多證券交易所: BLCO)("Bausch + Lomb")的完全分離具有戰略意義。Bausch Health董事會授權管理層及其子公司Bausch + Lomb的管理層探索潛在的出售,這只是完成分離所考慮的幾個期權之一。該過程正在進行中。尚未作出進行任何特定交易的決定,也無法保證這將導致交易的達成。」
While the Company normally would not comment on deal negotiations, CIRO requested confirmation of a potential sale process given stock volatility often associated with market rumors. Bausch Health does not intend to provide additional detail until further disclosure is appropriate or necessary."
「雖然公司通常不會對交易談判進行評論,但CIRO要求確認由於市場傳聞而引起的股市波動,潛在的出售過程。Bausch Health不打算在進一步的披露合適或必要之前提供額外的細節。」
Bausch Health is traded on both the New York Stock Exchange and Toronto Stock Exchange.
Bausch Health在紐約證券交易所和多倫多證券交易所上市交易。
About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, medical aesthetic devices, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information, visit and connect with us on LinkedIn.
關於Bausch Health
Bausch Health Companies Inc.(紐交所/多倫多證券交易所: BHC)是一家全球多元化的藥品公司,通過我們的不懈努力改善醫療保健結果。我們開發、製造和銷售一系列主要在胃腸病學、肝病學、神經學、皮膚病學、醫療美容設備、國際藥品和眼健康領域的產品,通過我們對Bausch + Lomb的控股權。我們的目標是成爲一家全球整合的醫療保健公司,受到患者、醫療保健專業人士、員工和投資者的信任與重視。更多信息,請訪問並在LinkedIn上與我們聯繫。
Forward-looking Statements
This news release may contain forward-looking statements within the meaning of applicable securities laws, including the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about the potential sale or full separation of Bausch + Lomb. Forward-looking statements may generally be identified by the use of the words "will," "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular, Bausch Health can offer no assurance as to whether the full separation of Bausch + Lomb will occur (including as a result of a potential sale or otherwise) or the timing or approval of any such separation. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
前瞻性聲明
本新聞稿可能包含適用證券法下的前瞻性聲明,包括1995年美國私人證券訴訟改革法案的安全港條款,包括關於Bausch + Lomb潛在出售或完全分離的聲明。前瞻性聲明通常可以通過使用「將」、「預期」、「希望」、「預計」、「打算」、「計劃」、「應該」、「可能」、「會」、「認爲」、「受制於」和變化或類似表達等詞語來識別。這些聲明既不是歷史事實,也不是未來表現的保證,基於管理層當前的預期和信念,並且受某些風險和不確定性的影響,這些因素可能導致實際結果與前瞻性聲明中描述的結果有顯著不同。特別地,Bausch Health無法保證Bausch + Lomb的完全分離是否會發生(包括可能的出售或其他方式)或任何此類分離的時間或批准。實際結果有其他風險和不確定性,這些與Bausch Health整體業務更廣泛相關,包括在Bausch Health最近的年度和季度報告中詳細描述的內容,以及不時在Bausch Health其他向美國證券交易委員會和加拿大證券管理局的文件中詳細描述的內容,這些因素在此通過引用而包含在內。提醒讀者不要對這些前瞻性聲明給予不當依賴。這些前瞻性聲明僅在本稿日期時有效。公司不承擔更新任何這些前瞻性聲明以反映此新聞稿日期後事件、信息或情況或反映實際結果的義務,除非法律要求。
Investor Contact:
Garen Sarafian
ir@bauschhealth.com
(877) 281-6642 (toll free)
投資者聯繫人:
加倫·薩拉非安
ir@bauschhealth.com
(877) 281-6642(免費)
Media Contact:
Katie Savastano
corporate.communications@bauschhealth.com
(908) 569-3692
媒體聯繫人:
凱蒂·薩瓦斯坦諾
corporate.communications@bauschhealth.com
(908) 569-3692
SOURCE: Bausch Health Companies Inc.
來源:bausch health公司。
譯文內容由第三人軟體翻譯。